Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 511

• Price / Volume Information    Yesterday's Closing Price: $28.46 Daily Weekly Monthly 20 Day Moving Average: 1,579,527 shares Shares Outstanding: 101.86 (millions) Market Capitalization: $2,898.83 (millions) Beta: 2.12 52 Week High: $36.44 52 Week Low: $13.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.04% 3.94% 12 Week 5.06% 4.93% Year To Date 2.67% 2.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - Cambridge,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com https://beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Sravan Emany - Chief Financial Officer Bethany Cavanagh - Senior Vice President; Finance Graham Cooper - Director Mark Fishman - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 101.86 Most Recent Split Date: (:1) Beta: 2.12 Market Capitalization: $2,898.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 7.29% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.33 Price/Cash Flow: - Price / Sales: 20.74 EPS Growth vs. Year Ago Period: 90.83% vs. Previous Quarter: 90.91% Sales Growth vs. Year Ago Period: 279.52% vs. Previous Quarter: 1,076.62% ROE 12/31/25 - -30.65 09/30/25 - -42.86 06/30/25 - -43.15 ROA 12/31/25 - -23.73 09/30/25 - -31.45 06/30/25 - -31.06 Current Ratio 12/31/25 - 13.09 09/30/25 - 6.02 06/30/25 - 6.75 Quick Ratio 12/31/25 - 13.09 09/30/25 - 6.02 06/30/25 - 6.75 Operating Margin 12/31/25 - -239.82 09/30/25 - -744.41 06/30/25 - -661.31 Net Margin 12/31/25 - -57.24 09/30/25 - -744.41 06/30/25 - -661.31 Pre-Tax Margin 12/31/25 - -57.24 09/30/25 - -744.41 06/30/25 - -661.31 Book Value 12/31/25 - 12.20 09/30/25 - 9.52 06/30/25 - 10.35 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©